To commemorate the 50th anniversary of the Society of Toxicology, this special edition article reviews the history and current scope of xenobiotic metabolism and transport, with special emphasis on the discoveries and impact of selected ''xenobiotic receptors.'' This overall research realm has witnessed dynamic development in the past 50 years, and several of the key milestone events that mark the impressive progress in these areas of toxicological sciences are highlighted. From the initial observations regarding aspects of drug metabolism dating from the midto late 1800's, the area of biotransformation research witnessed seminal discoveries in the mid-1900's and onward that are remarkable in retrospect, including the discovery and characterization of the phase I monooxygenases, the cytochrome P450s. Further research uncovered many aspects of the biochemistry of xenobiotic metabolism, expanding to phase II conjugation and phase III xenobiotic transport. This led to hallmark developments involving integration of genomic technologies to elucidate the basis for interindividual differences in response to xenobiotic exposures and discovery of nuclear and soluble receptor families that selectively ''sense'' the chemical milieu of the mammalian cell and orchestrate compensatory changes in gene expression programming to accommodate complex xenobiotic exposures. This review will briefly summarize these developments and investigate the expanding roles of xenobiotic receptor biology in the underlying basis of toxicological response to chemical agents.
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Overview
In this contribution, we provide a brief review of the history of xenobiotic metabolism, discuss current concepts, and provide comment on the toxicological implications of these processes. Indeed, in the past 50 years, much has been gleaned regarding our mechanistic understanding of chemical toxicities contributed by these coordinate biotransformation systems. From the early discoveries of these pathways, our scientific perspective has witnessed extraordinary advances led by the availability of new technologies and breakthroughs in areas encompassing biochemistry, molecular biology, genetics, and explosive growth in all the ''omics'' sciences. Yet, many issues surrounding the toxicology of chemical exposure and geneenvironment interactions remain to be elucidated, and it is clear that the next 50 years of toxicological research will result in yet further astounding advances in our perspective of toxic mechanisms as well as risk characterization related to xenobiotic exposures. A particular focus of this review will include discussion of the recent state of knowledge encompassing several key transcriptional regulators of xenobiotic enzyme expression, specifically, the xenosensing receptors, constitutive androstane receptor (CAR), pregnane X receptor (PXR), peroxisome proliferator-activated receptors (PPAR) a, PPARb/d, PPARc, and aryl hydrocarbon receptor (AHR). To begin this review, we provide below a brief history of biotransformation discovery.
Phase I Biotransformation
Although several enzyme systems participate in phase I metabolism of xenobiotics, perhaps the most notable pathway in this scheme is the monooxygenation function catalyzed by the cytochrome P450s (CYPs; P450s). The CYPs detoxify and/ or bioactivate a vast number of xenobiotic chemicals and conduct functionalization reactions that include N-and Odealkylation, aliphatic and aromatic hydroxylation, N-and Soxidation, and deamination. Examples of toxicants metabolized by this system include nicotine and acetaminophen, as well as the procarcinogenic substances, benzene and polyaromatic hydrocarbons. The discovery of the CYPs dates back to 1958 when Martin Klingenberg initially reported his observation of a carbon monoxide (CO)-binding pigment present in rat liver microsomes that was characterized by absorbance spectra at 450 nm (Klingenberg, 1958) . The spectra remained an anomaly until the work of Ryo Sato and Tsuneo Omura, published in 1962 (Omura and Sato, 1962) , provided the critical evidence that the CO chromaphore was a hemoprotein. They further described the properties of the protein, ascribing the term, CYP. Prior to these events, research conducted by Alan Conney and the Millers in the United States (Conney et al., 1956 ) and H. Remmer in Germany (Remmer, 1959) demonstrated that rates of hepatic drug metabolism could be induced or enhanced by pretreatment of animals with several types of compounds, including phenobarbital (PB) and 3-methylcholanthrene (3-MC); however, the identities of the enzymes responsible for these biotransformation events were not known at the time. Also in the 1950's, the work of R. T. Williams from the United Kingdom greatly expanded our scope of xenobiotic metabolism, elucidating the chemistries and reactions of a great many compounds. His achievements are summarized in a book that he authored in 1959, entitled, ''Detoxication mechanisms: the metabolism and detoxication of drugs, toxic substances and other organic compounds'' (Williams, 1959) . In his book, he established the terms phase I and phase II biotransformation, which are still used today, to denote the biphasic nature of metabolism and together account for a large extent of chemical detoxication that occurs in mammalian organisms. Another hallmark contributor to the field of xenobiotic metabolism was Bernard B. Brodie, who served as chief of the Laboratory of Clinical Pharmacology at the U.S. National Institutes of Health from 1950 to 1970 and headed a prolific group that made many substantive contributions to the study of P450 biochemistry. To commemorate his achievements, the American Society of Pharmacology and Experimental Therapeutics presents a biennial B. B. Brodie Award to recognize outstanding contributors to the research area of drug metabolism. Several of the investigators whose names follow are noted recipients of this prestigious award. Regarding some specific hallmarks of P450 achievement, Sladek and Mannering (1966) were the first to observe that 3-MC induction resulted two CO absorption peaks in liver microsomes and suggested that these were likely representative of two different forms of P450. In further studies, Alvares et al. (1967) termed these peaks, P448 and P450, with the P448 peak indicative of the 3-MC-inducible cytochrome. The field appeared to struggle with the notion of one versus two P450s for some while. The next breakthrough in P450 research involved the successful isolation and reconstitution of the P450 system published in 1968 by Anthony Lu and Minor Coon (Lu and Coon, 1968) . Following on with these new methods, Dr Lu joined the HoffmanLaRoche group and in work there, together with Paul Thomas and Wayne Levin, used both biochemical and immunological approaches to distinguish six different P450s in rat livers (Thomas et al., 1976) . Parallel research in Fred Guengerich's laboratory was expanding these areas of investigation and reported, e.g., the successful purification of eight P450s from rat liver following treatments with several inducing agents (Guengerich et al., 1982) . Among some modern recipients of the B. B. Brodie award, the substantive contributions of Dan Nebert in mouse P450 and AHR genetics, Frank Gonzalez for the development of humanized and other transgenic mouse models of P450, and Eric Johnson for his contributions to the structural elucidation of the P450s are certainly deserving of recognition. Certainly, many other scientists have also contributed importantly in the area of phase I xenobiotic metabolism over the past 50 years, so, with apologies, space limitations have precluded their mention here. Suffice it to say that today, 57 functional P450 genes have been identified in the human, and as of 2009, over 11,000 individual P450s have been identified at the primary sequence level across all known species of organism! For more information on the nomenclature and statistics regarding the compiled aspects of the P450s, the reader is referred to the CYP homepage maintained by David Nelson (Nelson, 2009 ).
Phase II Biotransformation
As referenced earlier, contributions from the laboratory of R. T. Williams and others dating to the 1950's first contributed to the chemical elucidation of phase II xenobiotic metabolism (Williams, 1959) . In his book, Dr Williams proposed that foreign compounds were metabolized in two distinct phases: one including oxidations, reductions, and hydrolyses and the other comprised of conjugation reactions. Although these views were first published in 1959, the recognition and study of metabolic conjugates of parent xenobiotics occurred much earlier in the history of drug metabolism. In the mid-to late 1800's, various conjugates of drugs and other chemicals were first discovered and characterized, including conjugates possessing sulfate, glucuronic acid, mercapturic acid, methyl, and acetylated moieties (Caldwell, 1986; Smith and Williams, 1970) . In these studies and onward, it was increasingly realized that metabolic conjugates of xenobiotics were often markedly less toxic than the parent chemicals and/or the products of the phase I reactions. As is the case for the research on phase I biotransformation, research advances in the study of phase II metabolism saw explosive expansion from the late 1970's onward. Phase II biotransformation is catalyzed often by the ''transferase'' enzymes that perform conjugating reactions. Included in the phase II reaction schemes are glucuronidation, sulfation, methylation, acetylation, glutathione conjugation, and amino acid conjugation. The products of phase II conjugations are typically more hydrophilic than the parent compounds and therefore usually more readily excretable. Specific families of phase II xenobiotic-metabolizing enzymes include the UDPglucuronosyltransferases (UGTs), sulfotransferases (STs), N-acetyltransferases (arylamine N-acetytransferase; NATs), and S50 OMIECINSKI ET AL. glutathione S-transferases (GSTs) and various methyltransferases, such as thiopurine S-methyl transferase and catechol O-methyl transferase. Perhaps of particular note, the UGTs conduct glucuoronidation reactions, principally with electronrich nucleophilic heteroatoms, such as O, N, or S, present in aliphatic alcohols and phenols. This microsomal system is a principal player in phase II metabolism and is known for its high metabolic capacity but relatively low affinity for xenobiotic substrates ). There are > 10 UGTs in humans. STs also constitute a large multigene family of cytosolic enzymes that catalyze the sulfation of primarily aliphatic alcohols and phenols and represent another important phase II pathway noted for its high affinity for xenobiotic substrates but low capacity . The GSTs function as cytosolic dimeric isoenzymes of 45-55 kDa size that have been assigned to at least four classes: alpha, mu, pi, theta, and zeta; humans possess > 20 distinct GST family members (Boyer, 1989; Wilce and Parker, 1994) . There are two NATs, NAT1 and NAT2, that possess different but overlapping substrate specificities and can function to both activate and deactivate arylamine and hydrazine drugs and carcinogens (Sim et al., 2008) . In concert with the phase I enzymatic machinery, the phase II enzymes coordinately metabolize, detoxify, and at times bioactivate xenobiotic substrates. Although beyond the scope of this review, genetic polymorphisms in all these genes exist and epidemiological investigations have variously associated several of these polymorphisms with altered incidences of cancer and other toxicities derived from chemical and drug exposures. The next 50 years of toxicological research will need to confront the formidable challenges associated with discerning critical gene-gene interactions and gene-environmental interactions that dictate differences in interindividual susceptibilities to toxicities arising from xenobiotic exposures.
Phase III Biotransformation
Phase III biotransformation is a more newly coined descriptor that refers to active membrane transporters that function to shuttle drugs and other xenobiotics across cellular membranes. In contrast to the long-standing history of discovery in phase I and phase II metabolism, research in phase III/active transport dates to 1976, with the discovery by Juliano and Ling (1976) of a 170-kDa carbohydrate complex in the extracellular membranes of Chinese hamster ovary cells that functioned to modulate drug permeability. They termed this complex the Pglycoprotein (permeability glycoprotein). P-glycoprotein was the initial member of what are currently referred to as the ATPbinding cassette (ABC) family of drug transporters. This research area rapidly gained attention, as P-glycoprotein and subsequently other membrane transporters were recognized to function in the resistance of cancer cells to chemotherapeutics, a phenotype referred to as the multiple drug resistance (MDR) phenotype (Scotto, 2003) . The consequences of the MDR phenotype may be severe as cells can develop resistance not only to the selective agent but also cross-resistance to a broad spectrum of structurally and functionally distinct antibiotics and alkaloids. As with most areas of biology, the MDR genotypephenotype relationship is complex, with over 18 ABC genes associated with human disease (Dean and Annilo, 2005) . In addition to the ABC transporters, other important drug/ xenobiotic transporters include the organic anion transporters and organic cation transporters of the SLC22A superfamily and the organic anion-transporting polypeptides of the SLCO superfamily (Hagenbuch, 2010) . The reader is referred to the citations herein for further reading on this important category of xenobiotic modulators. Certainly, the next 50 years of toxicological research will be rich with respect to the further characterization of phase III biotransformation function and defining role in xenobiotic toxicity. In particular, research investigations on the transcriptional regulatory control of these important systems in target organs such as the liver, kidney, and central nervous system are only in their early stages and will likely represent the focus of intense investigation going forward.
Regulation of Biotransformation by Xenobiotic Receptors
Several different classes of xenobiotics are recognized for their ability to ''induce'' or enhance the transcription of genes encoding biotransformation enzymes and xenobiotic transporters in mammalian organisms. The evolution of the scientific endeavor relating to the study of xenobiotic metabolism has extended to the discovery and functional characterization of an intricate group of receptor systems that are now recognized as key regulators of the biotransformation process. These receptors function to regulate three phases of biotransformation (Kohle and Bock, 2009) . Given the critical modulatory roles played by these particular classes of ''xenobiotic receptors,'' the remaining portions of this article will focus on the history of discovery and current understanding of these specific receptors as defining regulators that underlie toxicological responses of mammalian organisms to xenobiotic agents. These xenobiotic receptors include members of the impressive superfamily of nuclear receptors, a large category that includes the steroid hormone receptors such as the estrogen and androgen receptors and the nonsteroid receptors such as CAR, PXR, and the PPARs (Chambon, 2005) . The AHR also functions to regulate a battery of genes encoding biotransformation function. Examples of prototypical chemical inducers that impinge upon these receptor systems include PB, a CAR activator; rifampicin, a human PXR activator; the fibrate drug, clofibrate, and the Wyeth compound 643, both PPARa activators; and the dioxin, 2, 3, 7, , an AHR activator.
The AHR is not a member of the nuclear receptor superfamily per se; rather, it is a soluble Per-Sim-ARNT (PAS) domain receptor (Hankinson, 1995) . Contained within the AHR is a basic helix-loop-helix motif (bHLH) localized to the amino terminus of the receptor, a motif shared by other members of the bHLH superfamily of receptors. This region is XENOBIOTIC METABOLISM, DISPOSITION, AND REGULATION BY RECEPTORS S51 involved in both DNA binding as well protein-protein interactions of the receptor. The receptor also has two PAS domains that exhibit homology to protein domains originally identified in Drosophila, found in the period (Per) and single minded (Sim) genes, as well as in the AHR#s dimerization partner the aryl hydrocarbon receptor nuclear translocator (ARNT). These domains variously support interactions with other PAS domain-containing proteins and also provide critical residues that facilitate ligand binding of the receptor. A Q-rich domain is localized to the receptor's carboxy terminus and provides interactions with nuclear coregulator proteins (Kumar and Perdew, 1999) .
Regarding the xenobiotic nuclear receptors, the structure and mechanism of action of most nuclear receptors is quite similar. In general, there are three functional domains: (1) Kumar and Thompson, 1999) . The ligandbinding domain at the carboxy terminus of the receptor is where endogenous or xenobiotic ligands bind resulting in a conformational change of the receptor that alters its biophysical properties. Many nuclear receptors require heterodimerization with retinoid X receptor (RXR) (Mangelsdorf and Evans, 1995) for DNA binding. The DNA-binding domain of the receptor is responsible for recognition of a receptor-specific response element consisting of a sequence of nucleotides in the promoter region of the target gene. The transactivation domains consist typically of a ligand-independent AF-1 domain in the amino terminus and a carboxy terminal ligand-dependent transcription AF-2 domain. These domains serve as protein-protein interfaces that direct recruitment of transcriptional coregulators to the target gene (Glass and Rosenfeld, 2000) . Interestingly, CAR lacks the AF-1 domain. With CAR as an exception (see below), both the nuclear receptors (NR) and the AHRs are ligand-activated transcription factors that dictate their pleiotropic responses upon xenobiotic activation through their respective abilities to modulate targeted gene expression responses. The following sections of this review will discuss the historical and toxicological aspects of selected xenobiotic receptor systems.
CONSTITUTIVE ANDROSTANE RECEPTOR (NR1I3)
Brief History and Overview CAR was initially identified as MB67 (based on the initials of Miriam Baes, who worked in Dr David Moore's laboratory), isolated as an orphan nuclear receptor from human liver (Baes et al., 1994) . Mouse CAR was isolated subsequently (Choi et al., 1997 ). An unusual property of this receptor relative to other nuclear receptors can be inferred by its name, in that the reference form or wild-type CAR does not require a ligand for its activation. CAR functions typically as a heterodimer with the RXRa and the dimer preferentially targets DNA motifs that possess 4 or 5 direct repeat elements (DR-4 or DR-5), although several other DNA motifs have also been characterized as interacting elements (Baes et al., 1994; Choi et al., 1997; Sueyoshi and Negishi, 2001 ). Anderson's research group was the first to characterize a ''phenobarbitalresponsive element'' in the 5#-flanking region of the PBinducible rat CYP2B2 gene (Trottier et al., 1995) , followed by the Negishi laboratory#s identification of the ''phenobarbital response enhancer module'' upstream of the PB-inducible mouse gene, Cyp2b10 (Honkakoski and Negishi, 1997) , both activated through CAR interactions. Using transgenic mouse constructs, the Omiecinski laboratory demonstrated that this modular region was required for PB responsiveness in vivo (Ramsden et al., 1999) . Other PB-inducible genes encoding proteins that function in all three phases of xenobiotic biotransformation have since been shown to possess similar modules in their upstream promoter regions (Swales and Negishi, 2004) . For example, CAR is known to upregulate genes that encode the xenobiotic-metabolizing enzymes CYP2B, CYP2C, CYP3A, NADPH-CYP reductase, STs, UGTs, and GSTs (Ueda et al., 2002) , as well as the xenobiotic transporters, Mrp2 and Mrp4 (Assem et al., 2004; Kast et al., 2002) . In addition, results from gene expression profiling experiments have further identified a role for CAR in the regulation of many other functionally distinct genes (Ueda et al., 2002) . The ensuing years since the discovery of CAR have been marked with efforts of many laboratories that have defined the important role of this receptor as a mediator of xenobiotic induction responses, its role in toxicological outcomes following xenobiotic exposures, and more recently the impressive roles that this receptor plays in regulating energy metabolism and lipid homeostasis (Dekeyser and Omiecinski, 2010; Moreau et al., 2008) . These aspects of CAR function are briefly reviewed in the following sections.
Xenobiotic/Ligand Activation CAR activation can be achieved either through direct ligand binding within the ligand-binding pocket of the receptor or through indirect activation mechanisms, which are poorly understood. Interestingly, both these modes of interaction trigger release of the receptor from a cytoplasmic tethering complex where it is then freed to undergo nuclear translocation followed by dimerization to its RXRa nuclear partner and binding of the receptor dimer to requisite DNA motifs associated with CAR-inducible genes (Mutoh et al., 2009) . For example, the prototypical inducer PB is a representative of a large class of structurally diverse xenobiotics that induce mammalian biotransformation activities. Although PB induces biotransformation largely, if not exclusively, through its modulation of CAR (Scheer et al., 2008) , PB is not a direct ligand for the receptor and is thus an indirect activator (Moore et al., 2000b Fig. 1 ) Tzameli et al., 2000) . Whether direct or indirect acting, CAR xenobiotic activators appear to function by triggering release of the receptor from a cytoplasmic tethering complex, allowing the receptor to translocate to the nucleus, heterodimerize with its protein partner, RXRa, and interact at targeted genomic elements to modulate transcription responses (Dekeyser and Omiecinski, 2010; Moreau et al., 2008; Mutoh et al., 2009) . Many drugs, natural product-derived substances, and other xenobiotic agents have now been identified as CAR activators (Chang and Waxman, 2006) , establishing CAR as a critical effector of xenobiotic function and toxicity. Because of its high level of constitutive activity, a number of ligands for CAR are referred to with the unusual descriptor of ''inverse agonists,'' reflecting their ability to bind as ligands to the receptor but functioning to reduce the overall level of receptor activity.
More recently, variants of human CAR have been identified that arise through alternative RNA splicing. Two of these variants, termed CAR2 and CAR3, contain short 4 and 5 amino acid insertions, respectively, within the ligand-binding domain of the receptor (Auerbach et al., 2003) . Estimates of their RNA expression levels indicate that CAR2 and CAR3 may comprise up to 50% of the CAR pool in human liver (Dekeyser et al., 2009; Ross et al. 2010) . Both these CAR variants possess unusual functional biology in that they are not constitutively active like the reference form of the receptor, rather they are ligand activated. Using in silico modeling approaches as well as data from ligand activation studies, the five amino acid insertions in CAR3 appear not to interfere with the receptor's ligand-binding pocket, suggesting that CAR3 may serve as reasonable surrogate CAR in studies of ligand specificity analyses (Auerbach et al., 2005; Faucette et al., 2007) . However, similar assessments of CAR2 suggest that its four amino acid insertions may alter the shape of the ligand-binding pocket and alter its ligand specificity with respect to reference CAR (Auerbach et al., 2003) . For example, the ubiquitous plasticizer and environmental contaminant, di(2ethylhexyl) phthalate (DEHP), is a highly potent and selective CAR2 activator (Dekeyser et al., 2009) . It is noteworthy to point out that these human CAR variants are not present in rodents; therefore, standard rodent models may not be sufficient to assess human CAR receptor function. Further studies will be required to better determine the toxicological and physiological impact in human tissues of the composite nature of CAR structural variation.
Chemical Toxicity
Although CAR#s history is relatively short, CAR function has been variously associated with both protection from and a facilitator of chemical toxicities. For example, mice that are deficient for the CAR receptor are much more susceptible to hepatotoxicity resulting from acetaminophen exposure (Zhang et al., 2002) , a drug that is responsible for the majority of cases of acute liver failure seen clinically in the United States (Lee, 2003) . Mechanistically, the sensitivity of CAR-null mice to acetaminophen may involve the deficiency in these mice in the induction of the phase II protective function of GST-Pi (Zhang et al., 2002) . As a parallel in CAR's history, it was found that a traditional Chinese tea, Yin Chen, used to treat neonatal jaundice contains as a principle component, 6,7-dimethylesculetin, subsequently identified as a human CAR activator (Huang et al., 2004a) . As bilirubin clearance is facilitated by UGT 1A1 (UGT1A1), an enzyme function included in the battery of CAR-responsive genes, it appears that these inductive effects triggered by CAR activation may be protective for cases involving hyperbilirubinemia. Other dietary components, including certain flavonoids, have also been identified as CAR modulators (Yao et al., 2010) , as have a number of medicinal chemicals such as the antimalarial drug, artemisinin (Burk et al., 2005) , the antiemetic, meclizine (Huang et al., 2004b) , the antiseizure medication, phenytoin (Wang et al., 2004) , and the antifungal agent, clotrimazole (Moore et al., 2000b) . Along with PXR, CAR expression appears to offer a protective role against bile acid-induced toxicities, reflected in the hepatic toxicity initiated by exposure to lithocholic acid (Zhang et al., 2004) . Thus, the role of CAR as a mediator of chemical toxicity and as a modulator of chemically induced disease is impressive, with the examples cited reinforcing the concept that CAR functions as an integral xenobiotic sensor and a powerful biological rheostat, tuning the response of cells and organ systems to xenobiotic exposures in both humans and many other vertebrate species.
Tumor Promotion
PB is nongenotoxic; yet, in rodents, PB has long been noted for its capacity to act as an effective tumor-promoting agent in the development of rodent hepatocellular carcinoma (HCC). Although PB is a very effective indirect CAR activator, standard initiation-promotion studies comparing tumorigenesis in wildtype versus CARÀ/À mice have demonstrated clearly the requirement for CAR expression in the development of mouse HCC, following promotion with either the indirect CAR activator, PB, or the direct mouse CAR activator, TCPOBOP, a similarly nongenotoxic agent (Huang et al., 2005; Yamamoto et al., 2004) . Hepatomegaly in these models was similarly CAR dependent. The study of Huang et al. (2005) also utilized a mouse CAR-deficient line that was humanized with human CAR such that expression of the human receptor was selective for the liver. When those humanized CAR mice were subjected to a 0.05% PB diet for 1 week, clear evidence for both hepatomegaly as well as liver hyperplasia were obtained (Huang et al., 2005) . In apparent contrast, a recent report by Ross et al. (2010) examined these parameters in a human CAR knock-in mouse model and demonstrated that only heptomegaly and not hyperplasia resulted in animals dosed daily for 4 days with PB. The reasons for these apparent differences are not clear but may lie in the nature of the mouse models used to generate the results. Mechanistically, GADD45B (Yamamoto et al., 2010) , an antiapoptotic factor, as well as Mdm2 (Huang et al., 2005) , a negative regulator of the p53 tumor suppressor, have been implicated as pathways activated by CAR and contributory to the enhanced tumorigenic response in CAR wild-type animals.
In other investigations relating to the promotional effects of PB in mice, convincing results have been reported demonstrating an important role of connexin 32 in the promotional aspects of PB-induced hepatocarcinogenesis (Moennikes et al., 1999) . Furthermore, initiation-promotional studies conducted with connexin 32À/À mice demonstrated that PB was ineffective in promoting hepatocarcinogenesis in connexin 32-deficient animals (Moennikes et al., 2000) . These latter effects are likely related to the inability of PB to block gap junctional intercellular communication among liver hepatocytes-an underlying promotional mechanism that has been advanced for PB and as well as other tumor-promoting agents. Intriguingly, the potential function of CAR as a regulator of intercellular communication has not yet been explored.
Despite the otherwise compelling results and mechanistic roles advanced for CAR in the development of liver cancer in mice, it is noteworthy that in human investigations, rather powerful results, including those from very large retrospective epidemiological studies, examining the long-term effects of PB usage in human patients, have revealed no increase in incidence of HCC (Ferko et al., 2003; Lamminpaa et al., 2002; Vazquez and Marigil, 1989 ). Yet, PB appears to function similarly as a human CAR activator and gene inducer in human hepatocytes (Faucette et al., 2007; Kodama and Negishi, 2006; Olsavsky et al., 2007) , and in S54 OMIECINSKI ET AL. transgenic mice humanized for either the human CAR or PXR receptor. CAR, and not human PXR, appears to function as the primary mediator of PB activation responses (Scheer et al., 2008) . These issues have interesting and likely important toxicological implications for appraisal of human versus rodent tumorigenesis and raise critical risk assessment questions regarding the mode of action relevance of rodent liver tumors to human cancer risk (Holsapple et al., 2006) .
Physiology
In recent years, the role of CAR has expanded far beyond that of a xenobiotic-sensing receptor and regulator of xenobiotic metabolism. It is now clear that CAR also contributes to physiological function, regulating processes that include glucose homeostasis, lipogenesis, and energy metabolism. With respect to glucose homeostasis, wild-type mice treated with the selective CAR activator, TCPOBOP, demonstrate improved insulin sensitivity and protection from developing obesity following high-fat diets in direct contrast to CARÀ/À mice . The metabolic benefit of CAR activation was also demonstrated in the leptin-deficient ob/ob mice . These effects are attributed to the mobilization of several pathways, impacting gluconeogenesis, inhibition of lipogenesis, and enhanced peripheral fat mobilization ). These particular effects were not observed in corresponding studies performed in PXR mouse models. Other investigators have similarly reported a role for CAR in the modulation of type II diabetes, with CAR activation in mice improving glucose tolerance, insulin sensitivity, and reduction of serum glucose levels (Dong et al., 2009 ). Both of these recent studies are consistent with previous observations in humans that PB treatments decrease serum glucose levels in diabetic patients (Lahtela et al., 1985) . Although the exact mechanisms responsible for CAR's modulation of these physiological conditions are likely complex, one point of intersection may relate to the ability of both CAR and PXR to inactivate FoxO1 transcriptional activity (Kodama et al., 2004) . FoxO1 is a fork head transcription factor that positively controls genes involved in gluconeogenesis and is a target of insulin's repressive effects on the gluconeogenic pathway (Moreau et al., 2008 ). CAR's apparent role in the regulation of energy metabolism is perhaps interrelated and intriguing. CAR appears to function in thyroid hormone metabolism, as wild-type mice treated with TCPOBOP exhibit decreased levels of circulating thyroxine (T4), in contrast to CARÀ/À mice, an effect that has been attributed, at least in part, to the CAR-mediated induction of T4 metabolizing enzymes such as Ugt1a1 and several Sult pathways (Maglich et al., 2004; Qatanani et al., 2005) . Finally, CAR may affect lipid metabolism through cross talk with other NRs. A recent report suggested that CAR may inhibit lipogenesis by antagonizing the lipogenic effect of liver X receptor (LXR) (Zhai et al., 2010) . For more detailed discussions of these aspects of CAR's physiological roles, the reader is referred to several recent reviews (Gao and Xie, 2010; Konno et al., 2008; Moreau et al., 2008) .
PREGNANE X RECEPTOR (NR1I2) Brief History and Overview
Four years after the discovery of CAR, Kliewer et al. (1998) characterized a clone from a mouse liver expressed sequence tag database that exhibited homology to ligand-binding domains of a number of nuclear receptors. Following isolation of a full-length clone and subsequent characterization efforts, this orphan receptor was termed the PXR, with its name derived from the observation that the receptor was activated by pregnane (21-carbon) steroids such as pregnenolone 16a-carbonitrile (PCN), a synthetic glucocorticoid antagonist that had previously been recognized as an efficacious inducer of the CYP3A family of steroid hydroxylases . The human PXR, initially termed steroid and xenobiotic receptor or SXR, was first reported by Evans and colleagues (Blumberg et al. 1998) . PXR is now recognized as another key xenosensing member of the NR1I nuclear receptor subfamily, functioning in parallel with CAR as a chemical sensor and gene modulator (Reschly and Krasowski, 2006) . Like CAR, PXR forms a heterodimer with RXRa and, following ligand activation, interacts with a set of core gene promoter elements within xenobiotic-responsive enhancer modules that consist typically of DR-3 or ER6 motifs. CYP3A genes from various mammalian species are of particular interest as critical targets, in part because of the prominent role that CYP3A isoforms play in the metabolism of many pharmaceutical substances and other xenobiotics (Timsit and Negishi, 2007) . Both CAR and PXR are expressed at comparatively high level in liver tissues. Since their respective discoveries, research on PXR and CAR biology and their roles in toxicology have seen explosive growth.
Xenobiotic/Ligand Activation CAR and PXR exhibit overlap with respect to their abilities to bind multiple ligands, and each receptor's repertoire of interacting ligands is species specific. For example, PCN binds to the rodent forms of PXR, whereas rifampicin is selective for human PXR and TO901317 is a ligand for both human and mouse PXR (see Fig. 1 ) (Lehmann et al., 1998; Mitro et al., 2007) . Further examples of xenobiotics that exhibit human CAR selectivity include carbamazepine, efavirenz, and nevirapine, whereas selective human PXR activators include nifedipine, lovastatin, and hyperforin-a component of St John's wort (Chang and Waxman, 2006; Faucette et al., 2007; Moore et al., 2000a; Watkins et al., 2003) . In addition to shared overlap among chemical ligands, PXR and CAR also share overlap with respect to their gene targets. For example, XENOBIOTIC METABOLISM, DISPOSITION, AND REGULATION BY RECEPTORS S55 each receptor appears capable of transcriptionally activating CYP2B6 and CYP3A4 in humans, as well as activation of distinct gene targets (Maglich et al., 2002) . Therefore, PXR and CAR appear to function as a dynamic and parallel set of gene regulators, casting a broad detection net that senses the intracellular chemical milieu and accordingly modulates gene expression networks in the cell to accommodate the ongoing and changing patterns of chemical signaling.
With respect to the evolutionary nature of these receptors, both PXR and CAR are remarkable among the nuclear receptors in that they each demonstrate marked sequence divergence across animal species, despite very little sequence variation between humans (Reschly and Krasowski, 2006) . In further view of this point, the respective crystal structures obtained from mouse and human reveal that both PXR and CAR show considerable sequence variation across species, even among amino acid residues that interact directly with chemical ligands (Suino et al., 2004; Watkins et al., 2002; Xu et al., 2004) . The crystal structures also indicate that the ligandbinding domain of reference CAR is a well-formed pocket with a volume of~600 Å , whereas the pocket of PXR consists of an apo-volume of 1300 Å , with a shape that is flexible and capable of accommodating a more diverse array of potential ligands than that for CAR (Moore et al., 2006) .
Physiological and Toxicological Implications
Given their promiscuity in ligand specificities and overlapping gene targets, perhaps it is not surprising that PXR and CAR cross talk with coordinate regulatory pathways that converge on toxicological endpoints such as xenobiotic detoxication, adverse drug reactions, drug interactions, and bile acid toxicity, in addition to pathophysiological conditions including energy and lipid metabolism and cholestatic liver disease. Several of these considerations have been reviewed briefly in previous sections. As a more thorough review of these topics is beyond the scope of this article, the reader is referred to a number of recent publications and references therein that discuss these aspects in impressive detail Kodama et al., 2004; Moore and Kliewer, 2000; Stedman et al., 2005; Timsit and Negishi, 2007; Wada et al., 2009) . Given the first discoveries of CAR and PXR in 1994 and 1998, respectively, research into the expanding roles of these and other xenoreceptors has provided a remarkable new base for which to identify and characterize mechanisms and modes of toxicity associated with many foreign chemicals. The next years of toxicological research will undoubtedly see the intersection of current and future technologies enabling the ascertainment of genomic networks, their regulation, and interplay with the metabolome as contributors to altered biological responses triggered by xenochemical exposures, together with the real-world complexities embodied by factors such as interindividual variability in response.
PPAR ALPHA (NR1C1) Brief History and Overview
The phenomenon of peroxisome proliferation was first reported by several groups in the mid-1960's (Hess et al., 1965) . These investigators demonstrated significant increases of rat hepatic peroxisomes in both size and number in response to the hypolipidemic drug, clofibrate. In addition to peroxisome proliferation and hepatomegaly, peroxisomal fatty acid oxidation is induced, and long-term administration of hypolipidemic drugs causes hepatocarcinogenesis (Reddy et al., 1976) . A number of structurally diverse compounds were later identified that share the morphological and biochemical response of clofibrate and deemed ''peroxisome proliferators'' (PPs). During the mid-1980's, it was suggested that the biological effects induced by PPs were mediated by an unidentified cytosolic receptor that modulated gene expression to cause the pleiotropic effect of these chemicals (Reddy and Lalwani, 1983) . In 1990, a receptor termed PPAR was cloned from mouse liver using the estrogen receptor DNA-binding domain as a probe (Issemann and Green, 1990) . Discovery of PPAR has proven to be pivotal to the understanding of how PPs regulate gene expression and ultimately result in toxicity. As with CAR and PXR, PPARs are members of the nuclear receptor superfamily of transcription factors, similar in both structure and function to the steroid, thyroid, and retinoid receptors (Chambon, 2005) . The multifaceted responses of PPARs are mediated by three subtypes expressed in different tissues and at different times in development. The subfamily has been defined as PPARa (NR1C1), PPARb (also called PPARd and NUC1, NR1C2), and PPARc (NR1C3), each with a possibility of different ligands, target genes, and biological niche (Vanden Heuvel, 2004) . PPARs have been cloned in several species, including humans, rodents, amphibians, teleosts, and cyclostoma. In numerous cell types from ectodermal, mesodermal, or endodermal origin, PPARs are coexpressed, although their concentration relative to each other varies widely (Beck et al., 1992) . PPARa is highly expressed in cells that have active fatty acid oxidation capacity including hepatocytes, cardiomyocytes, enterocytes, and the proximal tubule cells of kidney. The PP response (hepatomegaly, increased peroxisome enzymes) is due almost exclusively to the PPARa subtype and will be the focus of the subsequent discussion.
Xenobiotic/Ligand Activation
The PPAR/RXRa complex controls gene expression by interacting with specific DNA response elements (PP response elements) located upstream of target genes (Tugwood et al., 1992) . Members of the RXRa-interacting subgroup of NRs typically bind to DNA elements containing two copies of direct repeat arrays spaced by 1-6 nucleotides (DR-1-DR-6). The idealized consensus binding site (AGGTCA) is similar for most members of this class of NR with the specificity dictated by the number of nucleotides between half-sites as well as the 5# flanking elements (Juge-Aubry S56 OMIECINSKI ET AL. et al., 1997). In the case of PPARa, a DR-1 motif is preferred with PPAR interacting with the 5# repeat and RXRa binding to the 3# motif (IJpenberg et al., 1997) .
As was introduced earlier, the idea of receptor ''activation'' denotes an alteration in the three dimensional structure of the receptor complex such that it is able to regulate gene expression. The physical alteration that is initiated by ligand binding may include events such as loss of heat shock proteins and chaperones, nuclear translocation, and protein turnover. The first class of PPARa activators included the PPs. PPs are a diverse class of chemicals and include the fibrate class of hypolipidemic drugs (clofibrate and ciprofibrate), WY-14,643 (often used as the prototypical PP), commercially used plasticizers (phthalates), steroids (dehydroepiandrosterone), and fluorinated fatty acid analogs (perfluorooctanoic acid [PFOA] and perfluorooctanesulfonic acid). It was nearly 30 years after the discovery of peroxisome proliferation that the target for these compounds was identified as PPARa. Subsequently, a large numbers of other exogenous activators of the PPARs have been identified, many of which are able to activate the three subtypes with varying efficacy and potency, whereas others have been developed as specific ligands (reviewed in Peraza et al., 2006) . In addition to these xenobiotic agonists, natural and endogenous regulators of PPARa activity have been delineated. PPARa was the first transcription factor identified as a prospective fatty acid receptor. Natural PPARa ligands in human serum include palmitic acid, oleic acid, linoleic acid, and arachidonic acid. Competition binding assays and cell-free ligand-sensing assays have been utilized to unequivocally demonstrate that fatty acids bind directly to PPARa. Notably, PPARa is the only PPAR subtype that binds to a wide range of saturated fatty acids. The lipoxygenase metabolite 8(S)-hydroxyeicosatetraenoic acid (HETE) was identified as a high-affinity PPARa ligand, although it is not found at sufficient concentrations in the correct tissues to be characterized as a natural ligand (reviewed in Peraza et al., 2006) . Because no single high-affinity natural ligand has been identified, it has been proposed that one physiological role of PPARa may be to sense the total flux of fatty acids in metabolically active tissues.
Biological/Functional Aspects
Peroxisomal, mitochondrial, and microsomal fatty acidmetabolizing enzymes are all increased by PPs. Furthermore, liver messenger RNAs (mRNAs) encoding proteins involved in lipid transport including fatty acid-binding protein, fatty acid transporters, lipoprotein lipase, and apolipoproteins are also regulated by these chemicals (Woods et al., 2007) . Expression of mRNAs encoding other lipid-related proteins that are altered as a result of PPs include 3-hydroxy-3-methylglutaryl-Coenzyme A synthase, lecithin:cholesterol acyl transferase, stearoyl-CoA desaturase 1, fatty acid synthase, S14, and malic enzyme, which are involved in cholesterol metabolism and lipogenesis. In addition to modifying gene expression essential to lipid metabolism, PPs can also influence mRNAs encoding proteins that regulate cell proliferation or the acute-phase response. Lastly, PPARa can mediate alterations in mRNAs associated with steroid metabolism (17b-hydroxysteroid dehydrogenase), prostaglandin synthesis (cylcooxygenase 2 [COX2]), iron metabolism (transferrin), nitrogen metabolism (glutamic-oxaloacetic transaminase and glutamic-pyruvic transaminase), and hepatitis B viral replication (Woods et al., 2007) .
Although it is clear that PPARa is critical in the regulation of lipid metabolism and that this receptor likely regulates cell proliferation/apoptosis underlying PP-induced hepatocarcinogenesis, the precise roles for some of these alterations in gene expression are not understood. There are several PP-responsive genes with a link to cell cycle control. Induction of the oncogenes c-Ha-ras, jun, and c-myc by PPs has been reported, and the ability to induce these genes correlates well with tumor-promoting potential. Gene expression profiling has been performed on a wide variety of PPs including monoethylhexylphthalate, clofibrate, WY-14,643, and PFOA, to name a few (reviewed in Woods et al., 2007) . All compounds caused an induction of genes involved in fatty acid metabolism, cell proliferation, and acute-phase proteins and a suppression of genes associated with gluconeogenesis. It is generally believed that the similar responses of the PPs are those that are regulated via PPARa, although each chemical may have their own individual off-target effects.
As outlined in the first part of this review, the metabolism of lipophilic xenobiotics, including drugs and nutrients, involves a coordinated process of biotransformation and transport, ultimately aimed at detoxifying and eliminating potentially harmful compounds. Most of the tissues and organs that express PPARa are well equipped with diverse and various drug metabolism enzymes including phase I (oxidative) and phase II (conjugative) metabolizing enzymes as well as phase III transporters. Many members of the NR superfamily, including PPARa, function as master regulators of the adaptive response of an organism to xenobiotics via regulation of phases I, II, and III enzymes (reviewed in Eloranta et al., 2005; Urquhart et al., 2007; Xu et al., 2005a) . In addition to induction of peroxisomal b-oxidation, PPARa agonists increase the oxidation of fatty acids, which may impact subsequent metabolism. The most studied such gene is CYP4A11, which plays a central role in the hydroxylation of fatty acid derivatives and cholesterol metabolism. Fibrates suppress bile acid synthesis via PPARa-mediated downregulation of cholesterol 7a-hydroxylase and sterol 27-hydroxylase expression (Luci et al., 2007) . Human hepatic hydroxysteroid sulfotransferase (Sult2A) gene is induced by fibrates in a PPARa-dependent manner (Fang et al., 2005) . PPARa is a crucial regulator of basal and fibrate-activated murine UGT2B gene expression (Barbier et al., 2003) . ABC transporter A1 (ABCA1) is a major regulator of high-density lipoprotein (HDL) biogenesis and is a transporter of xenobiotics.
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Although the transcription factor LXR alpha is most known for regulation of ABCA1, there is interplay between LXRa and the PPARs. Overexpression of either PPARa or PPARc by transfection enhanced LXRa and ABCA1 gene expression by PPAR agonists (Barbier et al., 2004) . The induction of (ABCB4) Mdr2 mRNA and Mdr2 protein levels by fibrates is mediated by PPARa (Barbier et al., 2004) .
Toxicological Implications
PPARa agonists are collectively referred to as PPs because of the hyperplastic effects on liver peroxisomes following exposure in rodents (Reddy and Krishnakantha, 1975) . In addition to peroxisomal proliferation, the size and number of hepatocytes also increase, causing significant liver enlargement. Chronic administration of PPs in rodents leads to liver tumorigenesis by a nongenotoxic mechanism (Marsman and Popp, 1994) . These two phenomena (hepatic peroxisome proliferation/hepatomegaly and hepatocarcinogenesis in rodents) are seen with this class of compound and are dependent on the presence of PPARa (Klaunig et al., 2003) . Other toxic responses have been reported for PPs. For example, male reproductive and developmental toxicity and carcinogenic effects in testis, pancreas, and kidney have also been associated with chronic administration of several PPARa agonists (Biegel et al., 2001; Kurokawa et al., 1988) . However, this is not seen with all PPs, and there is either lacking or conflicting evidence whether PPARa is the key mediator (reviewed in Peraza et al., 2006) .
In 1995, the PPARa-null mouse was first described (Lee et al., 1995) . Targeted disruption of the murine PPARa gene was not developmentally lethal, thus providing an excellent model to examine the role of this protein in homeostasis, toxicity, and cancer. In the initial report, PPARa-null mice were described as refractory to peroxisome proliferation, hepatomegaly, and increased expression of mRNAs encoding peroxisomal and microsomal fatty acid-metabolizing enzymes. Subsequently, this mouse model has been used extensively to examine the role of the PPARa in PP-hepatocarcinogenesis, lipid homeostasis, and alterations in gene expression elicited from a variety of stimuli such as feeding experimental diets, fasting, and cold acclimation (Gonzalez and Shah, 2008; Klaunig et al., 2003) . Combined, these data have provided definitive in vivo evidence that the PPARa has a critical role in modulating gene expression to maintain lipid homeostasis. Furthermore, these reports conclusively demonstrate that the PPARa is the only member of this receptor subfamily capable of mediating peroxisome proliferation and, most importantly, hepatocarcinogenesis induced by PPs.
Long-term administration of PPs causes hepatocarcinogenesis in rodent models (Klaunig et al., 2003) . The carcinogenic effect of these chemicals is only seen when there is significant peroxisome proliferation (i.e., greater than fourfold increase in peroxisomal fatty acyl-CoA oxidase activity) (Ashby et al., 1994) . PPs that cause hepatocarcinogenesis include the fibrate class of hypolipidemic drugs, WY-14,643, dehydroepiandrosterone, DEHP, and trichloroethylene (reviewed in Gonzalez and Shah, 2008) . The incidence of hepatocarcinogenesis in wild-type mice fed the potent PP WY-14,643 for 11 months is 100%, whereas PPARa-null mice are refractory to this effect (Peters et al., 1997) . Microscopic examination of livers from PPARanull mice fed WY-14,643 also failed to identify any preneoplastic lesions. Thus, it is clear that the carcinogenic effect of these chemicals is mediated by PPARa; however, the specific mechanisms underlying this effect have not been fully elucidated. Furthermore, it is likely that a species difference in sensitivity to PPs exists, and this will be discussed later. A number of possible mechanisms for PP-induced hepatocarcinogenesis have been hypothesized, including (1) increased oxidative damage to intracellular macromolecules (DNA, protein, and lipids) that contribute to gene mutations indirectly, (2) increased cell replication in the presence of damaged cells, and (3) inhibition of apoptosis, resulting in the persistence of damaged cells.
There is considerable debate concerning the mechanisms by which PPs cause liver tumors in rodent models and whether these chemicals represent a human cancer risk. It is well established that long-term administration of PPs results in hepatocarcinogenesis in rats and mice (reviewed in Klaunig et al., 2003) . In contrast, liver tumors are not found in Syrian hamsters after longterm administration of PPs. Similar investigations in nonhuman primates indicate that these species are also refractory to the PPinduced liver cancer, although these experiments were not carried out over the life span of the animals. Consistent with this idea, hepatic peroxisome proliferation is not found in nonhuman primates treated with these chemicals. Liver biopsies from humans treated with gemfibrozil, clofibrate, or fenofibrate for periods ranging from 27 to 94 months did not reveal convincing evidence of peroxisome proliferation, supporting the hypothesis that humans are less responsive to PPs. Further support of this idea is provided by two limited epidemiological studies that showed no evidence of increased cancer risk as a result of fibrate therapy (reviewed in Klaunig et al., 2003) . Although these observations suggest that a significant species difference in response to PPs exists, it is critical to delineate the mechanisms of this putative difference in order to increase the confidence of risk assessments made for this class of chemicals.
An important advance in understanding the human relevance of PP-hepatocarcinogenesis came with the development of the ''humanized'' PPARa mouse (Cheung et al., 2004) . This line expresses the human receptor in liver in a PPARa-null background by placing the human PPARa (hPPARa) complementary DNA under control of the Tet-Off system of doxycycline control with the liver-specific LAP1 (C/EBPb) promoter (reviewed in Gonzalez and Shah, 2008) . Humanized PPARa mice were resistant to WY-14,643-induced hepatocarcinogenesis after 11 months of WY-14,643 feeding in contrast to a 100% incidence in the wild-type mouse group (Morimura et al., 2006) . Subsequent analysis indicated that these species differences are likely because S58 OMIECINSKI ET AL. of increased cell proliferation mediated by PPARa-dependent downregulation of a microRNA causing increased expression of oncogenes; an effect not found with hPPARa (Shah et al., 2007) . These findings suggest that the species-specific effects of fibrates are likely because of differences in the profile of genes activated by mPPARa versus hPPARa following fibrate treatment (Gonzalez and Shah, 2008) .
In summary, PPs are a diverse class of chemicals that are capable of producing a consistent pleiotropic response. The effects observed in rodent liver include peroxisome proliferation, hepatomegaly, regulation of gene expression, cell cycle control, and, ultimately, carcinogenesis. The majority of biological effects induced by PPs are mediated by the PPARa and include physiological, toxicological, and carcinogenic pathways. Acting as transcription factors, PPARa functions in classic nuclear receptor fashion by ligand binding, heterodimerization, recruitment/dissociation of coactivators/corepressors, and modulation of transcription after binding to specific responsive elements of target genes. Definitive evidence of the biological and toxicological role of this receptor has been provided by extensive analysis of PPARa-null mice. 
Brief History and Overview
The initial search for nuclear receptors that mediated the biological effects of PPs (later learned to be PPARa agonists) led to the discovery of PPARs, which stemmed from the initial identification of PPARa (Issemann and Green, 1990 ), as described above. PPARb/d (also referred to as PPARb, PPARd, Faar, and NUC1) was first identified in Xenopus (Dreyer et al., 1992) . Subsequent cloning of the mammalian PPARb/d did not reveal close homology with the Xenopus gene and was thus named PPARd in mice (Kliewer et al., 1994) , Faar (fatty acid-activated receptor) in rat (Amri et al., 1995) , and NUC1 in human (Matsuo and Strauss, 1994) . It is now recognized that these receptors are orthologues and will be referred to as PPARb/d in this review. PPARb/d functions similarly as PPARa and PPARc as a ligand-activated transcription factor involving heterodimerization with RXRa, dissociation of corepressors, recruitment of coactivators with histone acetyl transferase activity essential for histone remodeling, and RNA polymerase to enable expression of target gene mRNA (reviewed in Peraza et al., 2006; Peters et al., 2008; Peters and Gonzalez, 2009) . Through this mechanism, PPARs can modulate important biochemical pathways by altering expression of different proteins in dynamic fashion (Fig. 2) expression and produce beneficial phenotypes in humans, in particular for regulation of glucose and lipid homeostasis and/or prevention of toxicity/cancer. Anti-inflammatory activities are also known to be associated with xenobiotics that target these receptors by interfering with other transcription factors (Tf) that modulate gene expression that regulate inflammatory responses. However, xenobiotics could also interfere with these functions leading to toxicity because of dysregulation of essential functions by receptor antagonism. Whether xenobiotic-induced enhancement of receptor-dependent functions directly causes, or contributes to, toxicity is also possible.
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have focused on rodents. In adult male rats, expression of PPARb/d mRNA is detected in adrenal gland, brain, heart, intestine, kidney, liver, and spleen but was notably higher in intestine, heart, and adrenal gland (Kliewer et al., 1994) . In situ hybridization and/or immunohistochemistry were used to examine expression of PPARb/d in adult and embryonic rat tissue (Braissant et al., 1996; Braissant and Wahli, 1998) . Although these studies indicate relatively ubiquitous expression of PPARb/d in most tissues including central nervous system, epidermis, kidney, liver, pancreas, heart adipose tissue, and intestine, the level of quantification was marginal so it is not possible to discern actual expression levels. The use of immunohistochemistry to quantify PPARb/d expression is also not suitable because of the high level of background associated with anti-PPARb/d antibodies (Foreman et al., 2009; Girroir et al., 2008) . Using RNase protection assays, expression of PPARb/d mRNA was quantified in adult rat tissues before and after food restriction (Escher et al., 2001) . This study was the most quantitative at the time and was consistent with previous studies showing high level of expression in intestine, heart, and liver. Comparatively lower level of expression of PPARb/d mRNA was also noted in adipose, brain, adrenal gland, lung, testis, thymus, and spleen. The more comprehensive studies examining PPARb/d expression in rats are still limited because of the lack, or limited nature, of protein expression. Using quantitative Western blotting, expression patterns of PPARb/d were determined in adult male mice (Girroir et al., 2008) . Results from this study confirm that expression of PPARb/d protein is highest in small and large intestine, keratinocytes, liver, and kidney and is also present at substantive levels in brain, heart, lung, testes, lung, skeletal muscle, spleen, and thymus. Interestingly, expression of PPARb/d protein was also found to be highest in the nucleus rather than cytosol (Girroir et al., 2008) . Furthermore, PPARb/d could be coimmunoprecipitated with its heterodimerization partner RXRa in the nuclear fraction, suggesting that PPARb/d is likely constitutively active because of the presence of an endogenous ligand.
Xenobiotic/Ligand Activation
PPARs are ligand-activated transcription factors that modulate gene expression critical for a variety of biological processes. It is thought that fatty acids and/or fatty acid derivatives act as endogenous ligands for PPARb/d. For example, oleic acid, linoleic acid prostacyclin I 2 , and 15-HETE are all reported to activate PPARb/d (Forman et al., 1997; Gupta et al., 2000; Naruhn et al., 2010) . In addition, synthetic xenobiotics have also been developed that exhibit high selectivity for PPARb/d. L165041 was the first xenobiotic with high affinity for PPARb/d described in the literature (Berger et al., 1999) , followed by the identification of two related compounds, GW501516 and GW0742 (Sznaidman et al., 2003) . The latter compounds exhibit affinity for PPARb/d in the low nanomolar range and 100-fold greater selectivity for PPARb/d as compared with PPARa or PPARc. The generation of xenobiotics with high affinity for PPARb/d was based on the idea that these compounds may be suitable for treating metabolic diseases for reasons described below. However, similar to what has been found for many candidate xenobiotics, adverse effects have also been noted in preclinical studies that may be because of interference with PPARb/d-dependent and/or PPARb/d-independent mechanisms of action (Fig. 2) .
Biological/Functional Aspects
Ligand activation of PPARb/d with GW501516 has been shown to improve dyslipidemias by increasing HDL cholesterol in preclinical studies including rodent and nonhuman primate models (reviewed in Billin, 2008) . Preclinical studies have also demonstrated that PPARb/d agonists can improve insulin resistance by increasing skeletal muscle fatty acid oxidation (Tanaka et al., 2003) and reducing serum glucose levels through a mechanism that requires PPARb/d (Lee et al., 2006a) . Increased skeletal muscle fatty acid catabolism and reductions in serum glucose in diabetic models appear to be mediated by upregulation of target genes that catabolize lipids or promote glucose clearance by PPARb/d.
In addition to its known role in metabolic function, PPARb/d has also been shown to be critical for modulation of terminal differentiation, cell proliferation, and apoptosis (reviewed in Burdick et al., 2006; Peraza et al., 2006; Peters et al., 2008; Peters and Gonzalez, 2009 ). This is particularly true for epithelial tissue. In both skin and colon, there is strong evidence that PPARb/d promotes terminal differentiation and through this mechanism maintains a central role in epithelial homeostasis. Activating PPARb/d in epithelium increases expression of proteins known to be required for terminal differentiation, and in the absence of PPARb/d expression, this effect is diminished Marin et al., 2006) . Whereas the role of PPARb/d in the regulation of terminal differentiation is well accepted, the effect of activating PPARb/d on cell proliferation is largely controversial. This is because of the large amount of conflicting literature (reviewed in Burdick et al., 2006; Peraza et al., 2006; Peters et al., 2008; Peters and Gonzalez, 2009 ). For example, ligand activation of PPARb/d has been reported to increase proliferation of human lung cancer cell lines (Han et al., 2008) . In contrast, other groups find that ligand activation of PPARb/d in human lung cancer cell lines either inhibits cell proliferation or has no effect at all (Fukumoto et al., 2005; He et al., 2008) . There are many other examples that exist (reviewed in Peters and Gonzalez, 2009) , and the reason for these disparities remains unknown. Moreover, it is also unclear how PPARb/d modulates apoptosis. It was originally suggested that PPARb/d promoted antiapoptotic activities by inhibiting expression of phosphatase and tensin homolog deleted on chromosome ten and increasing expression of 3-phosphoinositide-dependent protein kinase 1 and integrin-linked kinase (Di-Poi et al., 2002) . Combined, these changes were thought to increase S60 OMIECINSKI ET AL. phosphorylation of protein kinase B (also known as AKT) causing inhibition of apoptosis and cell survival (Di-Poi et al., 2002) . However, subsequent studies failed to replicate these findings using the same cell types (Burdick et al., 2007) . Thus, it is not surprising that some reports suggest that PPARb/d promotes antiapoptotic activity, whereas others do not (reviewed in Peters and Gonzalez, 2009 ). Because of these discrepancies in the literature, it is impossible to clearly understand the effect of ligand activation of PPARb/d on cell proliferation and/or apoptosis at this point ). In fact, to date, there are no confirmed, definitive gene targets that are conclusively known to be regulated by PPARb/d that either inhibit or promote cell proliferation and/or apoptosis.
Potent anti-inflammatory activities have also been described for PPARb/d and include mechanisms that are both receptor dependent and receptor independent (Kilgore and Billin, 2008) . For example, ligand activation of PPARb/d can inhibit expression of proinflammatory signaling molecules through mechanisms that include epigenetic interactions with other transcription factors such as nuclear factor kappa-light-chainenhancer of activated B cells (NFjB) (reviewed in Kilgore and Billin, 2008; Peters and Gonzalez, 2009 ). This has been observed in a number of models including nonalcoholic steatohepatitis and chemically induced liver toxicity (Nagasawa et al., 2006; Shan et al., 2008a,b) . Inflammation associated with colitis is greatly enhanced in PPARb/d-null mice, but ligand activation of PPARb/d did not inhibit inflammation in this model (Hollingshead et al., 2007) . This suggests that PPARb/d can also modulate inflammation through mechanisms that may not require an agonist. Moreover, there is also evidence that the anti-inflammatory activities of PPARb/d ligands can also be mediated by direct inhibition of enzymes such as myeopleroxidase . Thus, there are at least three distinct mechanisms by which PPARb/d agonists and/or PPARb/d can modulate inflammation: ligand-dependent epigenetic interactions, ligandindependent epigenetic interactions, and enzyme inhibition.
There are limited reports of toxicities associated with PPARb/ d ligands. Furthermore, there is considerable debate whether PPARb/d ligands promote, inhibit, or have no influence on cancer (reviewed in Peters et al., 2008; Peters and Gonzalez, 2009) . Some studies suggest that ligand activation of PPARb/d promotes carcinogenesis through ill-defined, and largely unconfirmed, mechanisms including increasing expression of putative target genes that promote cell proliferation (reviewed in Peters et al., 2008; Peters and Gonzalez, 2009 ). For example, it has been suggested that ligand activation of PPARb/d promotes colon cancer by increasing expression of vascular endothelial growth factor (VEGF) by directly upregulating expression (Wang et al., 2006) . However, subsequent analysis by others found no change in expression of VEGF by ligand activation of PPARb/d using the same human colon cancer cell lines (Hollingshead et al., 2007) . This emphasizes the need for rigorous evaluation of all mechanisms before solid conclusions can be drawn. It is also important to point out that studies suggesting procarcinogenic effects of PPARb/d ligands are at odds with other studies demonstrating essential homeostatic functions and/or inhibition of tumorigenesis (reviewed in Peters et al., 2008; Peters and Gonzalez, 2009 ). For example, it is difficult to reconcile how, or why, a protein that is expressed at such high levels in the colon (Girroir et al., 2008) would maintain cell function yet also promote cancer. For these reasons, it remains premature to clearly illustrate how PPARb/ d influences tumorigenesis as it remains possible that this receptor could be targeted for chemoprevention.
In contrast to the controversial nature of PPARb/d in cancer, there is clear evidence that GW0742, a potent PPARb/d agonist, can cause skeletal muscle myopathy. Skeletal muscle myopathy is known to occur in a small cohort (0.1-0.5%) of patients administered the fibrate class of hypolipidemic drugs, known PPARa agonists (Baer and Wortmann, 2007) . Administration of GW0742 at doses that would activate both PPARb/d and PPARa (! 100 mg/kg) causes skeletal muscle myopathy, but this effect is mediated by PPARa as this toxicity is not found in similarly treated Ppara-null mice (Faiola et al., 2008) . This is a good example of how off-target toxicities not mediated by the receptor of interest can confound interpretation of results and illustrates the need for carefully controlled studies using null mice as controls to demonstrate specificity.
Species Differences
Limited evidence exists suggesting that there are differences between rodent and human PPARb/d. Phthalate monoesters can activate mouse PPARa with greater potency and efficacy as compared with hPPARa but also compared with both PPARb/d and PPARc (Bility et al., 2004) . However, whereas some phthalate monoesters were marginally capable of transactivating mouse PPARb/d, this effect was not found with human PPARb/d, which exhibited no activity upon exposure to phthalate monoesters (Bility et al., 2004) . Whether this and/or related species differences exist for other PPARb/d activators remains uncertain. Moreover, it is worth noting that PPARb/d agonists have been developed that exhibit greater selectivity for human versus rodent PPARb/d. Thus, structural differences in agonists and/or the receptors because of polymorphisms might explain potential species differences.
Toxicological Implications
PPARb/d has well-characterized functional roles in glucose and lipid homeostasis, cellular differentiation, and inflammation. Xenobiotics that interfere with these critical receptor-mediated mechanisms could likely lead to a variety of toxicities (Fig. 2) . Recent development of new PPARb/d antagonists (Palkar et al., 2010; Shearer et al., 2010) will aid in determining whether interference with PPARb/d-dependent functions can lead to tissue-specific toxicities. In contrast to the clearly defined mechanism of PPARa-mediated liver cancer in rodents, there is limited, definitive evidence to date XENOBIOTIC METABOLISM, DISPOSITION, AND REGULATION BY RECEPTORS S61 demonstrating toxicities that are mediated by PPARb/d-dependent mechanisms resulting from xenobiotic exposure. Whether there are species differences in the response of PPARb/d to xenobiotics is uncertain. Although there are many reports suggesting that xenobiotics that activate PPARb/d promote tumorigenesis, this idea is highly contentious. Indeed, there are also many reports suggesting that PPARb/d might be targeted to prevent tumorigenesis. More studies are needed to elucidate how modulation of PPARb/d activity influences cancer. Myopathy induced by relatively high-dose exposure to one PPARb/d agonist is mediated by PPARa, demonstrating the need to control for off-target effects of xenobiotics that might target PPARb/d. Null mice and antagonists are ideally suitable and available for this purpose.
PPAR GAMMA (NR1C3) Brief History and Overview
The discovery of PPARc was facilitated by the original cloning and identification of PPARa (Issemann and Green, 1990) . PPARc was subsequently identified in Xenopus and mice because of sequence homology (Dreyer et al., 1992; Zhu et al., 1993) and later found to be a key transcription factor required for adipocyte gene expression and differentiation (Tontonoz et al., 1994a,b) . There are four different mRNA variants of PPARc: PPARc1, PPARc2, PPARc3, and PPARc4. Expression of PPARc1 and PPARc2 is driven by specific promoters on the same gene that leads to alternative splicing and the generation of two proteins that differ by~30 amino acids in the N-terminus (Fajas et al., 1997; Kliewer et al., 1994; Zhu et al., 1995) . PPARc3 and PPARc4 differ in their 5# untranslated region (Fajas et al., 1998; Sundvold and Lien, 2001 ). The functional role of PPARc4 is not well characterized. Many of the effects resulting from activating PPARc are mediated by PPARc1 and PPARc2. In the adult male rat, PPARc1 mRNA is expressed at the highest levels in brown and white adipose but is also expressed in colon, stomach, lung, heart, small intestine, skeletal muscle, testis, kidney, liver, adrenal gland, brain, and thymus (Escher et al., 2001) . Interestingly, expression of PPARb/d mRNA is markedly higher as compared with PPARc1 in adult rat colon (Escher et al., 2001) . Expression of PPARc2 mRNA is primarily found only in white and brown adipose in adult male rats (Escher et al., 2001) . Comprehensive, quantitative expression patterns of PPARc at the protein level have not been examined to date in any species, although there are many reports demonstrating protein expression in many cell types.
Xenobiotic/Ligand Activation
Polyunsaturated fatty acids and fatty acid derivatives such as 15-deoxy-delta12,14-prostaglandin J2 (15-dPGJ2), 9-hydroxyoctadecadienoic acid (HODE), 13-HODE, and nitrated fatty acids can all activate PPARc and may serve as endogenous ligands (Forman et al., 1997; Keller et al., 1993; Kliewer et al., 1997; Krey et al., 1997; Nagy et al., 1998; Schopfer et al., 2005) . Of these, 15-dPGJ2 has been extensively studied as a putative model endogenous ligand. Many synthetic xenobiotics have been developed that target PPARc for the treatment of diabetes because of their ability to decrease serum glucose. The best characterized class of xenobiotics that are potent PPARc agonists are the thiazolidinediones, which were isolated for their ability to improve serum glucose in a diabetic model prior to the identification of PPARc as their molecular target (Fujiwara et al., 1988; Lehmann et al., 1995) . Of the thiazolidinediones, troglitazone, rosiglitazone, and pioglitazone are probably the most extensively examined for their ability to activate PPARc. There are many other examples of compounds that have been developed that target PPARc such as a cyano derivative of betulinic acid and others (Chintharlapalli et al., 2007; Guo et al., 2010) , but the list is too exhaustive to include them here in this brief overview.
Biological/Functional Aspects
As noted above, PPARc was first shown to be essential for adipocyte differentiation because of its ability to modulate expression of genes required for adipogenesis (Tontonoz et al., 1994a,b) . Targeting PPARc has also become an effective approach for treating diabetes although the mechanisms underlying the hypoglycemic actions of thiazolidinediones remain somewhat obscure although it is thought that the white adipose tissue is a primary target via regulation of gene expression resulting in improved insulin resistance (Semple et al., 2006) . In addition to these well-characterized functions of PPARc, there is also evidence that PPARc can modulate cancer. Similar to PPARb/d, PPARc was initially thought to promote tumorigenesis because of reports suggesting that xenobiotics increased colon tumorigenesis (reviewed in Peraza et al., 2006) . However, it is now accepted that activating PPARc inhibits tumorigenesis, and this is because of PPARcmediated inhibition of cell proliferation, induction of differentiation and apoptosis, and various anti-inflammatory activities (reviewed in Michalik et al., 2004; Peraza et al., 2006) . In addition to receptor-dependent mechanisms induced by xenobiotics that target PPARc, there is also evidence that some of the chemopreventive properties are because of receptorindependent mechanisms. For example, inhibition of cell proliferation of human colon cancer cells by low-dose exposure to several xenobiotics that activate PPARc can be blocked by a PPARc antagonist, whereas induction of apoptosis by higher dose exposure to the same xenobiotics cannot be blocked by antagonism of PPARc (Chintharlapalli et al., 2005) . Similar to PPARb/d, PPARc also has potent anti-inflammatory activities in immune cells and other cell types. Xenobiotics that target PPARc can inhibit experimentally induced inflammation by S62 OMIECINSKI ET AL.
repressing expression of genes that promote inflammation such as tumor necrosis factor-a. For example, lipopolysaccharideinduced expression of inflammation-related genes in macrophages is inhibited by rosiglitazone and requires PPARc, as this inhibition is not found in cells that lack expression of PPARc (Welch et al., 2003) . These effects are mediated by transrepression whereby PPARc interacts with other transcription factors to effectively inhibit expression of proinflammatory signaling proteins (Glass and Saijo, 2010) . Collectively, PPARc has a number of important biological functions that can be targeted by xenobiotics.
Xenobiotics that target PPARc can also cause toxicities. Idiosyncratic liver injury occurred in humans treated with the first Food and Drug Administration-approved thiazolidinedione, troglitazone (Watkins, 2005; Watkins and Whitcomb, 1998) . The mechanisms underlying this toxicity remain unknown but could be related to genetic differences in more susceptible individuals (Chojkier, 2005) . PPARc agonists are also known to cause a variety of adverse side effects in cohorts of patients prescribed these xenobiotics for diabetes management including edema, weight gain, congestive heart failure, and bone fractures (reviewed in Peraza et al., 2006) . Because these adverse effects are not found in all patients treated with PPARc agonists, it is thought that there are also some genetic variations that may contribute to the mechanisms that underlie these phenotypes. There is evidence that PPARc may mediate some of these effects. For example, PPARc is required to mediate increased osteoclast activity in bone that may cause bone fractures (Wan et al., 2007) and may be required to mediate increased fluid retention via modulation of a kidney-specific sodium transporter (Guan et al., 2005) . Thus, xenobiotics can cause toxicity through mechanisms that may or may not require PPARc (Fig. 2) .
Species Differences
Species differences in PPARc activities have not been examined extensively as compared with PPARa. In rats, thiazolidinediones reduce infarct size and preserve left ventricular function resulting from myocardial ischemiareperfusion, whereas this effect is not found in a porcine model (Xu et al., 2005b) . Markers of liver toxicity are not detected in preclinical studies in rats, dogs, and monkeys but are observed in some humans treated with troglitazone (Watkins, 2005; Watkins and Whitcomb, 1998) . Polymorphisms in PPARc could also contribute to species differences but has been critically examined to date.
Toxicological Implications
PPARc has been relatively successfully targeted for the treatment of diabetes through the identification and characterization of xenobiotics that activate this receptor. This activity relies on the ability of PPARc to modulate gene expression that is central to glucose homeostasis; yet, the precise mechanisms of this effect remain uncertain. Substantive toxicities of xenobiotics that target PPARc have also been noted including congestive heart failure and bone fractures. Whether these effects are mediated exclusively by PPARc is not known, and it remains possible that other genetic variables participate in the mechanisms that cause these toxicities. Additionally, receptor-independent or off-target events could contribute to effects induced by xenobiotics that target PPARc (Fig. 2) . Furthermore, whether species differences exist in the activities associated with xenobiotics that target PPARc is unknown and could be influenced by polymorphisms in PPARc.
THE ARYL HYDROCARBON RECEPTOR (BHLHE76) Brief History and Overview
The AHR is a ligand-activated bHLH/Per-ARNT-Sim transcription factor that mediates the toxicity of TCDD, commonly referred to as dioxin. Upon agonist binding, the AHR, bound to a dimer of heat shock protein 90 and X-associated protein 2, translocates into the nucleus where ARNT displaces hsp90 and heterodimerizes with the AHR, as shown in Figure 3 (Beischlag et al., 2008) . The ligand-bound AHR-ARNT complex is then able to bind to a dioxin-responsive element (DRE) in the promoter of a wide range of genes involved in drug metabolism, such as Cyp1a and Cyp1b1, as well as growth and cell differentiation, such as Ereg and Snai2. The ability of AHR activation to enhance drug-metabolizing enzyme expression has been reviewed in another article in this volume. 
Xenobiotic/Ligand Activation
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The AHR is considered a promiscuous receptor that is capable of binding a large number of structurally diverse chemicals, select examples of which are shown in Figure 4 (Denison and Nagy, 2003) . The number of naturally occurring and man-made chemicals that that have been identified to bind the AHR continues to grow, giving the impression that in our diet there is a plethora of chemicals that can bind and activate the AHR at concentrations in the micromolar range. A number of carcinogens can interact with the AHR, leading to their subsequent bioactivation, such as benzo [a] pyrene and heterocyclic amines (Ma and Lu, 2007) . Structure-activity studies with dioxin congeners and other ligands revealed that high-affinity binding required that an AHR ligand was rectangular, planar, and hydrophobic with maximal dimensions of 14 3 12 3 5 Å (Gillner et al., 1993; Waller and McKinney, 1995) . Most of the naturally occurring AHR ligands identified, for instance, flavonoids and tetrapyroles, exhibit intermediate hydrophobicity and affinity for the AHR (Denison and Nagy, 2003; DiNatale et al., 2010a; Lu et al., 1996; Schroeder et al., 2010) .
There are significant species-specific differences in AHR ligand affinity. Initial studies on the human AHR revealed that the human receptor contains a point mutation in the ligandbinding domain (valine 381) that lowers its ability to bind TCDD by~10-fold compared with the Ah b allele of the mouse AHR (Ema et al., 1994; Harper et al., 1988; Ramadoss and Perdew, 2004) . This amino acid residue is an alanine in the mouse AHR and is found in the middle of the ligand-binding pocket according to a structural model (Murray et al., 2005) . However, recent studies have revealed that the indole derivative indirubin has higher affinity for the human AHR than its murine counterpart . These results prompted an examination of whether other indole derivatives of physiological significance can activate the human AHR. Surprisingly, indoxyl sulfate, the major metabolite of indole in mammalian organisms, is a relatively high-affinity ligand for the human AHR (Schroeder et al., 2010) . In primary human hepatocytes, 100nM indoxyl sulfate is capable of markedly inducing CYP1A1/2 mRNA levels. A survey of endogenous tryptophan metabolites has revealed that two metabolites of the indoleamine-2,3-dioxygenase pathway, kynurenic acid and xanthurenic acid, can significantly activate the human AHR (DiNatale et al., 2010a). Structure-activity studies indicate that the carboxylic acid group is important for binding, although this concept is in contrast to the traditional view of AHR ligands as hydrophobic neutral compounds. Interestingly, both kynurenic acid and indoxyl sulfate exhibit greater ability to activate the human AHR compared with the mouse AHR. The indoleamine-2,3-dioxygenase pathway is important in T-cell function and has been linked to local immune suppression in the tumor microenvironment (Muller et al., 2008) . What role the AHR may play in this phenotype remains to be investigated. The identification of potent endogenous AHR ligands should lead to a better understanding of TCDD-mediated dysregulation of key endogenous AHR signaling pathways.
Biological/Functional Aspects
The physiological role of the AHR continues to be an active area of investigation and was first explored through examination of the phenotype of Ahr-null mice. These mice exhibit a number of defects, such as immune system dysfunction, poor liver vasculature development, and reduced fecundity (McMillan and Bradfield, 2007) . This latter phenotype appears a consequence of multiple defects that result in lower conception rate, smaller litter size, and low pup survival rates (Baba et al., 2005) . Cardiovascular effects, such as a systemic hypertension and hypoxemia condition, have been observed in Ahr-null mice, depending on the altitude (Lund et al., 2008) . Perhaps, the area of AHR biology that has received the most recent attention is the ability of the AHR to influence T-cell differentiation. The AHR can play a role in the balance of T H 1 and T H 2 cells, as was established through the use of an AHR agonist M50367 that mediates a preference for increased T H 1 versus T H 2 cells (Morales et al., 2008; Negishi et al., 2005) . M50367 exposure in mice leads to a decreased response in an allergic experimental models. Differentiation of naive T cells leads to enhanced AHR expression and supports the concept that the AHR mediates key steps in this process. Interleukin 17 (IL17)-producing T helper cells (Th17) are a proinflammatory subset of T helper cells that play a critical role in the experimental development of autoimmune diseases, such as collagen-induced arthritis (Peck and Mellins, 2009) . The AHR plays an important role in the development of Th17 cells, both in in vitro and in vivo experimental models (Veldhoen et al., 2008 (Veldhoen et al., , 2009 ). Furthermore, the AHR appears to regulate signal transducer and activator of transcription 1 (STAT1) activation during T-cell differentiation into Th17 cells. The mechanism of action appears to be at least in part because of AHR binding directly to STAT1 (Kimura et al., 2008) . How the AHR activation occurs under physiological conditions is unknown, and whether these effects are mediated by endogenous ligands remains to be determined.
AHR and Inflammatory Signaling
There are numerous reports indicating that prolonged activation of the AHR via exposure to high levels of an AHR agonist leads to enhanced inflammatory signaling (Beischlag and Perdew, 2005; Kitamura and Kasai, 2007) . However, more recent studies have revealed that the AHR can mediate anti-inflammatory responses as well, through interference with NFjB signaling or repression of IL6 induction (Jensen et al., 2003; Tian et al., 1999) . In addition, it has been demonstrated that the AHR can attenuate cytokine-mediated induction of the acute-phase response gene expression in liver in a DRE-independent manner (Patel et al., 2009 ). This appears to be a selective response, considering that the AHR fails to influence the induction of Il8 or Nfkbia. However, the mechanism of repression remains to be determined. The ability of the AHR to attenuate acute-phase gene expression may point to a role for the AHR in helping to maintain homeostasis in the presence of inflammatory signaling in the liver.
It has been recently proposed that the AHR may also be an important new target for maintaining tissue homeostasis during chronic inflammatory diseases. Systemic inflammation usually leads to an acute-phase response in the liver because of the presence of circulating inflammatory cytokines such as IL6 and IL1B. This results in the activation of a number of transcription factors, such as STAT3, NFjB, and activator protein 1 (AP-1). These factors then bind to the promoters of a rather large subset of genes termed ''acute-phase,'' such as c-reactive protein, serum amyloid A (SAA), many complement factors such as C3, and tissue plasminogen activator (Gabay and Kushner, 1999) . This initial adaptive response is an important mechanism to enhance an animal#s response to bacterial invasion or other insults. Once the insult has been dealt with, there are feedback mechanisms that repress the acute-phase response. However, during chronic diseases such as cancer, inflammatory bowel disease, and rheumatoid arthritis, acute-phase protein levels remain high as the disease progresses (Malle et al., 2009) . In particular, SAA levels can reach as high as 2.2 mg/ml in serum and high levels of SAA can lead to amyloidosis (Wilkins et al., 1994) . For example, up to 50% of juvenile rheumatoid arthritis deaths are because of amyloidosis, most from end-stage renal failure (Gillmore et al., 2001; Savolainen and Isomaki, 1993) . In addition to high SAA levels leading to fibril formation and amyloidosis, recent studies examining the biological activity of SAA suggest that it may be a mediator of inflammation. SAA binds to formyl peptide receptor-like-1, receptor for advanced glycation end products, and Toll-like receptor 2 receptors; activation of these receptors leads to enhanced inflammatory signaling through activation of NFjB and AP-1 (Cheng et al., 2008; Lee et al., 2006b; Okamoto et al., 2008) . These reports clearly indicate a need for therapeutic intervention that would attenuate the acute-phase response in patients with chronic inflammatory diseases. Thus, the AHR, through its ability to attenuate acute-phase gene induction, may be an important therapeutic target.
Ligand-Selective AHR Modulators
The ability of the AHR to repress cytokine-mediated acutephase gene expression has allowed testing of the hypothesis that the AHR could be activated by ligands to induce non-DRE-mediated activities. This has led to the identification of AHR ligands that fail to elicit a DRE-mediated transcription, yet repress acute-phase gene expression, such as SGA360 (Murray et al., 2010a,b) . These studies have also led to the hypothesis that there are basically three types of AHR ligands, agonists, antagonists, and selective AHR modulators (SahRMss), and their various activities are outlined in Table 1 . Agonists exhibit the ability to induce both DRE-driven transcriptional activity and repression of acute-phase gene expression. In contrast, SahRMss are only capable of mediating repression of acute-phase gene expression (Fig. 5) . Other possible targets for SahRMs activity remain to be explored. A full antagonist fails to mediate any known AHR activity and would block both agonists and SahRMs from mediating their activities. The discovery of a full antagonist will provide a very useful reagent in the characterization of SahRMs. However, the identification of a full antagonist remains to be established. Without a clear definition of SahRMss, ligands may be found that exhibit partial agonist activity, non-DRE-mediated activity, and/or other yet to be determined mechanisms of activities. Thus, the term SAhRM can have different definitions, e.g., in one line of investigation this term is being used to describe an AHR ligand that can mediate repression of tumor cell growth and yield partial agonist activity (Fritz et al., 2009; Zacharewski et al., 1992) . The specific mechanisms of these effects have not been determined but may be DRE mediated. This is in contrast to the SAhRM activity described to elicit acute-phase gene expression repression, which is mediated through a non-DRE-driven mechanism and appears to be a cytoplasmic event.
Toxicological Implications
The various endpoints of dioxin toxicity have been extensively studied and reviewed (Birnbaum and Tuomisto, 2000; Gasiewicz et al., 2008; Knerr and Schrenk, 2006; Pelclova et al., 2006) . However, the precise molecular mechanisms that lead to various toxicity endpoints have been difficult to determine. One major reason for the lack of understanding of AHR-mediated toxicity is the need to better elucidate the physiological role of the AHR in cellular and whole-animal homeostasis. This in turn would lead to studies examining how dioxin alters the defined pathways. Another factor that has hampered progress in determining the biological and toxicological properties of the AHR is the large number of genes that can be regulated by the AHR in a tissue-and species-dependent manner. Like many transcription factors, the AHR can regulate gene expression through binding to cognate response elements or through cytoplasmic or nuclear proteinprotein interaction events.
Cancer Progression
The ability of the AHR to regulate CYPs that metabolize many carcinogens (e.g., polycyclic aromatic hydrocarbons and aflatoxin) to reactive intermediates that bind to DNA has placed the AHR as a central player in initiation of chemical carcinogenesis. Less understood is the role that the AHR plays in tumor promotion and progression to a metastatic phenotype. However, there is now a large body of evidence that indicates that the AHR regulates a battery of genes that contribute to an advanced maligant phenotype in various established tumor cell lines. Some examples include Slug, MMP-9, ABCG2/BCRP, FASCIN-1, Nedd9, COX2, VAV3, and Ube213 (Bui et al., 2009; Carvajal-Gonzalez et al., 2009; Degner et al., 2007; Ebert et al., 2005; Hashimoto et al., 2009; Ikuta and Kawajiri, 2006; Reyes-Hernandez et al., 2010; Villano et al., 2006) . In addition, studies have demonstrated that expression of the tumor-promoting cytokine IL6 in tumor cell lines is highly dependent on the presence of the AHR at the IL6 promoter . Furthermore, recent studies in T24 urothelial carcinoma (UC) cells, a UC-derived cell line, revealed that AHR expression plays an important role in a tumor invasion cell culture assay (Ishida et al., 2010) . The presence of the AHR greatly enhanced expression of MMP-1 and MMP-9 in T24 UC cells and may at least partially explain the invasion assay results. This group went on to utilize immunohistochemistry to examine AHR subcellular localization in 209 patient tumor sections with differing histological grades. The results revealed a highly significant correlation between long-term survival and a lack of nuclear AHR staining. Patients with high nuclear AHR levels had~50% lower survival rates. These results firmly support a role for the AHR in UC progression. Recently, the AHR has been shown to be highly expressed in hyperplasic breast samples and in breast cancer samples (Korzeniewski et al., 2010) . Also, as the cell phenotype progressed to a malignant phenotype, there was an increasing localization of the AHR in the nucleus. The AHR was found to play a role in centrosome amplification mediated in the absence of exogenous ligand in tumor cell lines. Interestingly, the addition of an AHR agonist inhibited the ability of the AHR to enhance centrosome amplification. Most likely, an AHR antagonist would also inhibit centrosome amplification, but this remains to be tested. In conclusion, it is becoming increasingly clear that the AHR plays a major role in the progression and aggressive phenotype of certain types of cancer. Furthermore, this suggests that the use of AHR antagonists or selective AHR ligands may have potential as a cancer therapy in the future.
To delineate which type of AHR-mediated activity leads to toxicity, genetically engineered mice that express mutant forms of the AHR are needed. Bradfield and coworkers have generated two useful mouse models: one in which the AHR fails to translocate and another where the AHR can heterodimerize with ARNT, yet fail to bind to DNA (Bunger et al., 2003 (Bunger et al., , 2008 . Both of these mutant AHR mouse models failed to exhibit either hepamegaly or thymic involution upon treatment with TCDD, in contrast to C57BL6/J mice. These results would indicate that TCDD toxicity is a nuclear event driven by the AHR-ARNT binding to DRE. In addition, both of these mice have a patent ductus venosus; a developmental defect observed in the absence of AHR expression (Lahvis et al., 2005) , indicating that the latter physiological endpoint requires DRE-mediated activity. These results narrow the focus on possible AHR regulation events that lead to dioxin toxicity.
SUMMARY
Tremendous progress has been made in the past 50 years elucidating functional roles for xenobiotic receptors that help to explain how chemicals modulate homeostasis and toxicity. The advent of modern molecular biological tools, together with advances in genetic engineering, genomics, transgenic models, and the development of high-affinity ligands have resulted in an enhanced understanding of the functional roles for these enigmatic receptors. Considering the pace of change in toxicological research, it is clear that we can continue to expect further advancement as science evolves. With an increased understanding of the physiological and mechanistic roles for these receptors, we will certainly be in an improved position to delineate more specifically how xenobiotic receptors modulate toxicities. With the further emergence and integration of technologies such as metabolomics, it is likely that we will achieve identification of the endogenous metabolites/chemicals that are metabolized by enzymes regulated by xenobiotic receptors. Given the major advances that have occurred in the recent past, the next 50 years of investigation promises to underscore a truly exciting time revealing further remarkable advances in receptor biology and the roles of the xenobiotic receptors as mediators of gene-environment interactions. 
